- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Can Global Policies to Boost Biosimilar Adoption Work in the US?
On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
On this episode of Not So Different, The Center for Biosimilars® celebrating Global Biosimilars Week—an annual advocacy campaign promoting the use of biosimilars worldwide orchestrated by the International Generics and Biosimilars Association.
Joining us for this special episode is Craig Burton, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines. Craig is a leading voice in the biosimilar space, and together, we’ll explore a fascinating and timely question: Can global policies to boost biosimilar adoption work in the US?
From government incentives and substitution policies to international trade agreements and health equity strategies, we’ll dive into lessons learned from around the world. How do Europe, Canada, Latin America, Australia, and others foster biosimilar growth—and what can the US learn from these approaches?
Show notes
To learn more about GBW, click here.
To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here.
To learn more about product hopping, click here.
To read part 1 of our GBW series, click here.
To read part 2 of our GBW series, click here.
To read part 3 of our GBW series, click here.
To hear another episode featuring more of Craig's thoughts on the Biden's administration's impact on the biosimilar industry, click here.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
